All In MedTech

FDA Clearance Tracker · DEN200026

EndeavorRx

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 19, 2026Latest source record: Jun 15, 2020 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

Decided

Jun 15, 2020

De Novo granted

Time to decision

60 days

Received Apr 16, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN200026
Device name
EndeavorRx
Applicant location
Boston, MA
Received
Apr 16, 2020
Decided
Jun 15, 2020
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 882.5803

Every decision under product code QFT

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Akili Interactive Labs, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.